Developer docs
API playgroundTry for free, no card

Search company profiles

Success TMS

Full company profile

uuid000ix5s

Namestring
Success TMS
Legal namestring
Greenbrook TMS NeuroHealth Centers
Websiteurl
successtms.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Success TMS is a private U.S. therapeutic clinic operator founded in 2017 and headquartered in Boca Raton, Florida, that administers non-medication and medication-assisted treatments for depression, primarily transcranial magnetic stimulation (TMS) and esketamine nasal spray. The company's two core offerings are NeuroStar TMS Therapy, an FDA-cleared, non-invasive magnetic-stimulation protocol targeting brain regions associated with mood regulation, and SPRAVATO (esketamine), an FDA-approved nasal spray from Janssen Pharmaceuticals indicated for treatment-resistant depression and MDD with suicidal ideation. Success TMS does not own the underlying device or pharmaceutical IP; it is an administrator and clinical-services provider running a multi-location U.S. clinic footprint.

The business model is direct-to-consumer healthcare delivered through owned physical clinics, complemented by a healthcare-provider referral channel ('For Providers'). Pricing is not publicly disclosed; reimbursement is driven by insurance billing, with the company accepting most major commercial plans, Medicare, and Medicaid at various locations and handling paperwork, claims filing, processing, and appeals on its own. The primary customer segment is patients with treatment-resistant depression who have not responded adequately to talk therapy or antidepressant medication, with a secondary segment of patients who prefer to avoid systemic drug side effects.

Growth has been physical rather than technological: scaling from a single 2017 founding site to a multi-state footprint supported by 251-500 employees. Marketing is multi-channel — website content, patient testimonials, online PHQ-10 and TMS-eligibility self-assessments, phone consultations, and a provider referral program. The company's competitive positioning rests on the FDA status of its administered modalities, in-house insurance handling, convenience of clinic locations, and specialist brand focus on depression remission. No proprietary technology, AI capabilities, or financial disclosures are present in the available data.

Short descriptiontext

Success TMS is a private, multi-location U.S. clinic operator founded in 2017 that administers FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine to patients with treatment-resistant depression, billing through major insurance plans including Medicare and Medicaid.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWest Palm Beach, United States
HQ citystring
West Palm Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
depression treatment, transcranial magnetic stimulation, TMS therapy, esketamine treatment, mental health services
Industry1 code
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Offices of Physicians, Mental Health Specialists621112
  • Outpatient Mental Health and Substance Abuse Centers621420
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Mental Health Services / Depression Treatment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Treatment Services
TypeSubscription Recurring
Description

Revenue generated from providing TMS therapy and esketamine nasal spray treatments to patients. The company handles insurance billing directly, filing and processing claims on behalf of patients. Treatments can be stand-alone or combined with existing medication regimens.

greenbrooktms.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D
Pricing details1 tier
1Insurance-based treatment pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Covered by most insurance plans including Medicare and Medicaid at various locations. Quote-based / Not publicly disclosed.

greenbrooktms.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1NeuroStar TMS Therapy
Description

FDA-cleared, non-medication depression treatment using transcranial magnetic stimulation technology.

greenbrooktms.com
+1 more record
Core offering1 text field

Success TMS is a therapeutic clinic that provides non-medication and medication-based treatments for depression, primarily NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy and SPRAVATO (esketamine) nasal spray treatments. The company targets patients with treatment-resistant depression or those seeking alternatives to traditional antidepressant medications, administering FDA-cleared/approved therapies at multiple US clinic locations while handling all insurance paperwork, claims filing, and appeals on behalf of patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Patient testimonials report relief from depression after first treatment session
Product overview1 text field

Greenbrook TMS offers two FDA-cleared/approved depression treatments: NeuroStar TMS Therapy (a non-medication transcranial magnetic stimulation therapy) and SPRAVATO (an FDA-approved esketamine nasal spray). Both treatments are designed for patients struggling with depression who have not found relief through traditional treatments like talk therapy or antidepressant medication.

Product and service2 records
1NeuroStar TMS Therapy
CategoryDepression treatment / TMS therapy
Description

FDA-cleared, non-medication transcranial magnetic stimulation therapy for depression that targets brain areas associated with mood regulation using magnetic pulses; intended for adult patients with depression who have not found adequate relief from talk therapy or oral antidepressants, or who want to avoid systemic drug side effects.

2SPRAVATO (esketamine) Nasal Spray Treatment
CategoryDepression treatment / esketamine therapy
Description

FDA-approved esketamine nasal spray treatment administered in-clinic for adults with treatment-resistant depression or depressive symptoms in adults with MDD with suicidal thoughts or actions; can be used as a stand-alone therapy or in combination with oral antidepressants.

Partnership3 partners
Strategic tierCoreTypeTechnology or Integration
Description

Greenbrook uses NeuroStar TMS Therapy, an FDA-cleared transcranial magnetic stimulation system for treating depression. The company operates as a treatment provider utilizing Neuronetics' proprietary TMS technology platform. NeuroStar is the technology provider while Greenbrook operates treatment centers.

2SPRAVATO (Janssen Pharmaceuticals)
Strategic tierCoreTypeTechnology or Integration
Description

Greenbrook provides SPRAVATO (esketamine) nasal spray treatments, an FDA-approved medication manufactured by Janssen Pharmaceuticals (a Johnson & Johnson company) for treatment-resistant depression. Greenbrook administers the treatment in its clinic locations.

greenbrooktms.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Greenbrook partners with major insurance companies for coverage of TMS and esketamine treatments. The company handles all paperwork, claims filing, processing, and appeals on behalf of patients. Coverage includes Medicare and Medicaid at various locations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Large publicly traded behavioral health services provider operating inpatient psychiatric facilities and outpatient programs. Provides a benchmark for specialty mental health services at scale, though broader in scope than Success TMS.

TypeBroad incumbent
Description

Direct-to-consumer mental health platform offering telehealth psychiatry, therapy, and medication management. Competes for the same patient acquisition channels and consumer mental health spend, though its delivery model is digital rather than in-clinic.

TypeBroad incumbent
Description

Enterprise mental health benefits platform connecting employees to therapy, coaching, and medication management. Represents the broader employer-funded mental health category in which Success TMS competes for specialty referrals.

TypeRegional player
Description

Outpatient behavioral health services provider focused on substance use disorder treatment. Operates in an adjacent behavioral health services niche with comparable multi-site clinic delivery model.

TypeBroad incumbent
Description

Large diversified hospital and behavioral health operator with significant inpatient psychiatric capacity. Broad incumbent in behavioral health services delivery, much larger and broader in scope than Success TMS.

TypeBroad incumbent
Description

Public online therapy platform serving consumers and enterprise clients. Adjacent behavioral health provider that competes for the same self-pay and employer-sponsored mental health patient pool as Success TMS.

TypeOthers
Description

Manufacturer of the NeuroStar TMS system used by Success TMS and now operator of Greenbrook clinics. Acts as a technology supplier and vertically integrated competitor shaping the broader TMS clinic economics.

TypeDirect peer
Description

Operated a multi-site US TMS clinic network using NeuroStar technology and SPRAVATO before being acquired by Neuronetics. Highly comparable specialty behavioral health clinic operating model targeting treatment-resistant depression.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Success TMS

Mental Health Services / Depression Treatmentsuccesstms.com

Success TMS is a private, multi-location U.S. clinic operator founded in 2017 that administers FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine to patients with treatment-resistant depression, billing through major insurance plans including Medicare and Medicaid.

What Success TMS does

Success TMS is a private U.S. therapeutic clinic operator founded in 2017 and headquartered in Boca Raton, Florida, that administers non-medication and medication-assisted treatments for depression, primarily transcranial magnetic stimulation (TMS) and esketamine nasal spray. The company's two core offerings are NeuroStar TMS Therapy, an FDA-cleared, non-invasive magnetic-stimulation protocol targeting brain regions associated with mood regulation, and SPRAVATO (esketamine), an FDA-approved nasal spray from Janssen Pharmaceuticals indicated for treatment-resistant depression and MDD with suicidal ideation. Success TMS does not own the underlying device or pharmaceutical IP; it is an administrator and clinical-services provider running a multi-location U.S. clinic footprint.

The business model is direct-to-consumer healthcare delivered through owned physical clinics, complemented by a healthcare-provider referral channel ('For Providers'). Pricing is not publicly disclosed; reimbursement is driven by insurance billing, with the company accepting most major commercial plans, Medicare, and Medicaid at various locations and handling paperwork, claims filing, processing, and appeals on its own. The primary customer segment is patients with treatment-resistant depression who have not responded adequately to talk therapy or antidepressant medication, with a secondary segment of patients who prefer to avoid systemic drug side effects.

Growth has been physical rather than technological: scaling from a single 2017 founding site to a multi-state footprint supported by 251-500 employees. Marketing is multi-channel — website content, patient testimonials, online PHQ-10 and TMS-eligibility self-assessments, phone consultations, and a provider referral program. The company's competitive positioning rests on the FDA status of its administered modalities, in-house insurance handling, convenience of clinic locations, and specialist brand focus on depression remission. No proprietary technology, AI capabilities, or financial disclosures are present in the available data.

Success TMS firmographics

Firmographics
Name
Success TMS
Legal name
Greenbrook TMS NeuroHealth Centers
Website
https://successtms.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Success TMS is a private, multi-location U.S. clinic operator founded in 2017 that administers FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine to patients with treatment-resistant depression, billing through major insurance plans including Medicare and Medicaid.
Ownership category
akta.pro rank

Success TMS industry classification

Industry
Product category
Mental Health Services / Depression Treatment
NAICS
Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Depression treatment
  • Transcranial magnetic stimulation
  • TMS therapy
  • Esketamine treatment
  • Mental health services

Where Success TMS is headquartered

Location

Headquarters

HQ city
West Palm Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Success TMS business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

  1. Clinical Treatment Services: Revenue generated from providing TMS therapy and esketamine nasal spray treatments to patients. The company handles insurance billing directly, filing and processing claims on behalf of patients. Treatments can be stand-alone or combined with existing medication regimens.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInsurance-based treatment pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Success TMS product offering

Product offering

Core offering

Success TMS is a therapeutic clinic that provides non-medication and medication-based treatments for depression, primarily NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy and SPRAVATO (esketamine) nasal spray treatments. The company targets patients with treatment-resistant depression or those seeking alternatives to traditional antidepressant medications, administering FDA-cleared/approved therapies at multiple US clinic locations while handling all insurance paperwork, claims filing, and appeals on behalf of patients.

Product overview

Greenbrook TMS offers two FDA-cleared/approved depression treatments: NeuroStar TMS Therapy (a non-medication transcranial magnetic stimulation therapy) and SPRAVATO (an FDA-approved esketamine nasal spray). Both treatments are designed for patients struggling with depression who have not found relief through traditional treatments like talk therapy or antidepressant medication.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroStar TMS Therapy: FDA-cleared, non-medication depression treatment using transcranial magnetic stimulation technology.
  • SPRAVATO

Products and services

  • NeuroStar TMS Therapy FDA-cleared, non-medication transcranial magnetic stimulation therapy for depression that targets brain areas associated with mood regulation using magnetic pulses; intended for adult patients with depression who have not found adequate relief from talk therapy or oral antidepressants, or who want to avoid systemic drug side effects.
  • SPRAVATO (esketamine) Nasal Spray Treatment FDA-approved esketamine nasal spray treatment administered in-clinic for adults with treatment-resistant depression or depressive symptoms in adults with MDD with suicidal thoughts or actions; can be used as a stand-alone therapy or in combination with oral antidepressants.

Quantifiable outcome

  • Patient testimonials report relief from depression after first treatment session

Companies that use Success TMS

Customer profile

Segments2 records

Ideal customer profiles1 record

Success TMS technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Success TMS partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • NeuroStar (Neuronetics)coreTechnology or IntegrationGreenbrook uses NeuroStar TMS Therapy, an FDA-cleared transcranial magnetic stimulation system for treating depression. The company operates as a treatment provider utilizing Neuronetics' proprietary TMS technology platform. NeuroStar is the technology provider while Greenbrook operates treatment centers.
  • SPRAVATO (Janssen Pharmaceuticals)coreTechnology or IntegrationGreenbrook provides SPRAVATO (esketamine) nasal spray treatments, an FDA-approved medication manufactured by Janssen Pharmaceuticals (a Johnson & Johnson company) for treatment-resistant depression. Greenbrook administers the treatment in its clinic locations.
  • Major Insurance CompaniescoreGTM or Marketing PartnerGreenbrook partners with major insurance companies for coverage of TMS and esketamine treatments. The company handles all paperwork, claims filing, processing, and appeals on behalf of patients. Coverage includes Medicare and Medicaid at various locations.

Recent moves6 records

Expansion highlights4 records

Success TMS competitors and assessment

Company assessment

Broad incumbents

  • Acadia Healthcare: Large publicly traded behavioral health services provider operating inpatient psychiatric facilities and outpatient programs. Provides a benchmark for specialty mental health services at scale, though broader in scope than Success TMS.
  • Cerebral: Direct-to-consumer mental health platform offering telehealth psychiatry, therapy, and medication management. Competes for the same patient acquisition channels and consumer mental health spend, though its delivery model is digital rather than in-clinic.
  • Lyra Health: Enterprise mental health benefits platform connecting employees to therapy, coaching, and medication management. Represents the broader employer-funded mental health category in which Success TMS competes for specialty referrals.
  • Universal Health Services: Large diversified hospital and behavioral health operator with significant inpatient psychiatric capacity. Broad incumbent in behavioral health services delivery, much larger and broader in scope than Success TMS.
  • Talkspace: Public online therapy platform serving consumers and enterprise clients. Adjacent behavioral health provider that competes for the same self-pay and employer-sponsored mental health patient pool as Success TMS.

Regional players

  • Behavioral Health Group: Outpatient behavioral health services provider focused on substance use disorder treatment. Operates in an adjacent behavioral health services niche with comparable multi-site clinic delivery model.

Others

  • Neuronetics: Manufacturer of the NeuroStar TMS system used by Success TMS and now operator of Greenbrook clinics. Acts as a technology supplier and vertically integrated competitor shaping the broader TMS clinic economics.

Direct peers

  • Greenbrook TMS: Operated a multi-site US TMS clinic network using NeuroStar technology and SPRAVATO before being acquired by Neuronetics. Highly comparable specialty behavioral health clinic operating model targeting treatment-resistant depression.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Success TMS social profiles

Digital presence

Success TMS compliance and trust

Trust signal

Compliance2 records

Success TMS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Success TMS leadership team

Management profile

Number of profiles

Success TMS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Success TMS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Success TMS

What does Success TMS do?

Success TMS is a therapeutic clinic that provides non-medication and medication-based treatments for depression, primarily NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy and SPRAVATO (esketamine) nasal spray treatments. The company targets patients with treatment-resistant depression or those seeking alternatives to traditional antidepressant medications, administering FDA-cleared/approved therapies at multiple US clinic locations while handling all insurance paperwork, claims filing, and appeals on behalf of patients.

Is Success TMS a public or private company?

Success TMS is a private company. It is classified as unknown and is currently operating.

When was Success TMS founded?

Success TMS was founded in 2017. It employs 11 to 50 people.

Where is Success TMS based?

Success TMS is headquartered in West Palm Beach, United States, in the North America region.

How does Success TMS make money?

One revenue line is on record: clinical Treatment Services.

Who are Success TMS's main competitors?

Broad incumbents on record are Acadia Healthcare, Cerebral, Lyra Health, Universal Health Services and Talkspace. Behavioral Health Group is listed as a regional player. Neuronetics is listed as an others. Greenbrook TMS is listed as a direct peer.

Does Success TMS have an API?

No public API is recorded for Success TMS.

What industry is Success TMS in?

Success TMS's product category is Mental Health Services / Depression Treatment. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 621112 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNeuronetics Reports Third Quarter 2021 Financial and Operating ResultsNeuronetics reported Q3 2021 revenue of $13.8 million, up 11% year-over-year, with a net loss of $8.2 million. The company signed exclusive agreements with Zion Healing and Success TMS, and expects full-year 2021 revenue between $53.3 million and $54.3 million.GlobeNewswireNeuronetics Celebrates 235,000 Treatment Milestone for Success TMSSuccess TMS, a provider of NeuroStar TMS therapy, delivered over 235,000 treatments to patients with major depressive disorder across the U.S. in just three years. The milestone brings the practice closer to its goal of one million treatments and reflects a 20% increase in demand over the past year.GlobeNewswireNeuronetics Announces Commercial Agreement with Success TMSNeuronetics announced an exclusive five-year commercial agreement with Success TMS, which will use Neuronetics' NeuroStar Advanced Therapy for treatment-resistant major depressive disorder. The deal includes a $10 million term loan to support Success TMS's expansion. Success TMS has delivered over 250,000 treatments across 30 sites in six states.PR NewswireSuccess TMS Turns Tragedy Into Hope For Those Struggling With DepressionSuccess TMS, a Transcranial Magnetic Stimulation provider founded by Jonathan Michel after losing his sister to depression, has grown to become the second-largest TMS provider in the United States with 32 offices across six states. The company offers an FDA-cleared, drug-free depression treatment covered by major insurance providers including Blue Cross Blue Shield, Aetna, Cigna, Humana, and Medicare. Michel's stated mission is to raise awareness about TMS as an alternative to conventional medication and electroconvulsive therapy while expanding access to treatment nationwide.PR NewswireNeuronetics® and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar® Advanced TherapyNeuronetics, Inc. (NASDAQ: STIM) announced a three-year partnership with Success TMS, a healthcare provider specializing in transcranial magnetic stimulation for depression, under which Success TMS will offer Neuronetics' NeuroStar Advanced Therapy system as its preferred TMS device at 21 locations across six U.S. states. Success TMS, founded by Jonathan Michel following his sister's death by suicide, has grown to become one of the leading TMS therapy providers in the United States, treating hundreds of patients daily. The partnership is expected to enable treatment of thousands of patients, with Success TMS planning aggressive expansion including new clinic launches in existing and new regions over the next 18 months.